1. What happened
Under the renewed data exclusivity agreement, GuideAI retains exclusive rights to use de-identified imaging generated across vRad's network to develop AI models. The issuer states that the dataset provides the foundation to train and validate GuideAI algorithms; detailed delivery, retention and downstream model-rights mechanics are not disclosed.
2. Buyer / seller
GuideAI Health is the AI buyer or model-development side. vRad (Virtual Radiologic) owns or contributes the proprietary corpus.
3. Economics
The renewed agreement's financial consideration, minimum commitments and pricing formula are not disclosed. Economics scope: No agreement value, per-study pricing, revenue share, equity component or other economic terms are disclosed.. Strategic Signal has not estimated undisclosed consideration.
4. Proprietary data
De-identified imaging data generated across vRad's national network of more than 2,100 U.S. hospitals and healthcare facilities, made exclusively available to GuideAI for development, training and validation of AI models for vascular-disease detection and characterization. Historical depth: The arrangement is a renewal of an existing data partnership, but the reviewed source does not disclose the original start date, number of studies or years of imaging history.. Refreshability: The renewed partnership covers imaging generated across an ongoing network of more than 2,100 hospitals and healthcare facilities, indicating a renewable flow; exact refresh cadence is not disclosed..
5. Rights and restrictions
Access is limited to the renewed vRad data partnership and AI-model development scope; detailed technical access controls are not disclosed. Ownership: No ownership transfer of vRad imaging data is disclosed.. Training: Permitted and expressly contemplated: GuideAI states that the imaging corpus provides a foundation to train its vascular-disease algorithms.. Post-training: Validation of GuideAI algorithms is expressly contemplated; fine-tuning and other post-training rights are not separately described..
6. Why the data matters for AI
Training, validating and expanding GuideAI models for detection and characterization of peripheral arterial and other vascular diseases from routine CT imaging. The imaging corpus contains clinically meaningful disease signals used for detection and characterization, but the disclosure does not establish linked treatment interventions and outcomes.
7. Asset Score — 93/100
Strategic Signal analysis. The exclusive national imaging corpus is large, real-world, renewable and directly useful for clinical-model training, though exact longitudinal depth and patient-level outcome linkage are not disclosed. Score coverage: 100%.
| Factor | Weight | Rating / 5 | Points |
|---|---|---|---|
| Uniqueness / scarcity | 12 | 4.5 | 10.8 |
| Historical depth | 8 | 4 | 6.4 |
| Decision → outcome richness | 13 | 4 | 10.4 |
| Decision Value Density | 13 | 5 | 13.0 |
| Real-world grounding | 10 | 5 | 10.0 |
| Domain economic value | 9 | 5 | 9.0 |
| Refreshability | 8 | 5 | 8.0 |
| Proprietary advantage | 9 | 5 | 9.0 |
| Model-learning usefulness | 10 | 5 | 10.0 |
| Non-replicability | 4 | 4.5 | 3.6 |
| Rights usability | 4 | 4 | 3.2 |
8. Transaction Signal Score — 55/100
Strategic Signal analysis. Exclusive model-development rights are unusually explicit, but economics and market price discovery are absent, materially limiting the transaction signal despite strong AI-use and rights clarity. Score coverage: 85%.
| Factor | Weight | Rating / 5 | Points |
|---|---|---|---|
| Disclosed economics | 16 | 0 | 0.0 |
| Clean price discovery | 16 | 0 | 0.0 |
| Separability of data consideration | 15 | 4 | 12.0 |
| Explicit training / model-improvement use | 14 | 5 | 14.0 |
| Clarity of rights purchased | 12 | 4.5 | 10.8 |
| Competing bids | 10 | Unknown | — |
| Strategic buyer quality | 6 | 3.5 | 4.2 |
| Repeatability / precedent value | 6 | 4.5 | 5.4 |
| Independent model-uplift evidence | 5 | Unknown | — |
9. M&A / valuation implications
Shows how a large clinical-network data owner can grant exclusive AI-model development rights without transferring ownership of the underlying corpus, potentially creating strategic scarcity for specialized healthcare AI developers.
10. Evidence boundary
The issuer release establishes the renewed exclusive rights, de-identified imaging scope, more than 2,100-hospital network, approximately 500-radiologist workflow, and training/validation purpose. Economics, term length, exact corpus size, delivery architecture, retention, derived-model ownership, sublicensing, geographic processing controls and independent model-uplift evidence are not disclosed.